China Life Insurance (Overseas) Company Limited Issuer Summary

Report date: 2026-08-26
Issuer: China Life Insurance (Overseas) Company Limited
Ticker focus: CHILOV
Sector: Hong Kong and Macau life insurance
Primary credit focus: issuer credit, insurance financial strength, parent-support expectation, insurance liabilities and investment assets, Hong Kong and Macau franchise, and the security risk of the Hong Kong Branch's USD subordinated capital bonds

1. Business Snapshot and Recent Developments

China Life Insurance (Overseas) Company Limited (China Life Overseas) is the sole wholly owned overseas subsidiary of China Life Insurance (Group) Company. Its reported business spans life insurance, pension and retirement-related products, investment, group insurance and operations in Hong Kong, Macau, Singapore and Indonesia. For this coverage, CHILOV is China Life Overseas and, where the security is discussed, the USD subordinated capital bonds issued by China Life Overseas' Hong Kong Branch. It is not China Life Insurance Company Limited, the mainland-listed insurer with stock codes 2628.HK and 601628.SH. The legal-entity distinction is decisive: it determines which financials apply, which regulatory capital regime matters and where the subordinated notes sit in the creditor waterfall.

The material development since the prior summary is publication in Macau Official Gazette No. 21 on 27 May 2026 of FY2025 summarized audited financial statements and an activity statement for China Life Overseas' Macau Branch. The disclosure gives a current, audited branch-level snapshot that had not been available in the prior report. It is nevertheless a narrow disclosure. It is not consolidated financial information for China Life Overseas, it is not a financial statement for the Hong Kong Branch, and it is not financial information for the listed mainland insurer. The distinction limits what the new data can prove about the credit of the USD subordinated bonds.

The Gazette states that the Macau Branch recorded premium business income of MOP12.95bn and profit after tax of MOP1.23bn in 2025. It reported total assets of MOP100.64bn, including MOP72.85bn of tangible and financial investments, while technical provisions were MOP51.30bn. The branch's balance-sheet total and its stated profit confirm a substantial and profitable Macau operation, subject to the limits of summarized accounts. They do not establish the profitability, capital resources, Hong Kong risk profile or call capacity of the broader company. The independent auditor reported an unmodified opinion on the underlying Macau Branch FY2025 audited financial statements, dated 29 April 2026, while also stating that the published summary does not include all disclosures required by Macau financial reporting standards.

The Company profile continues to show unaudited issuer-profile indicators, not audited Company financial statements: company assets of HKD452.8bn and combined revenue of HKD68.9bn as of end-December 2025, as well as Moody's A1 insurer financial strength rating and S&P A local-currency issuer credit and insurer financial strength ratings. The profile labels the asset figure as unaudited. The current Gazette information has a different entity scope, currency, accounting presentation and disclosure basis. It would therefore be wrong to add it to, reconcile it with, or use it as a replacement for the profile figures. Taken together, the sources show a sizeable Hong Kong-Macau insurance platform with a current audited Macau Branch filing, but not a full FY2025 financial package for the Company or Hong Kong Branch.

The 2023 offering circular for the Hong Kong Branch's USD2.0bn 5.35% dated subordinated capital bonds due 2033 remains the primary public source for the security terms and the latest detailed company-consolidated historical financial series found in this work. That circular showed China Life Overseas as an insurer whose financial profile is shaped by investment asset valuation, long-dated insurance liabilities, product mix, policyholder behaviour and regulatory capital. Its historical 2020-2022 figures cannot be treated as a seamless series with the Macau Branch's 2025 accounts, but they remain important context for explaining why a profitable branch does not settle the wider credit question.

The immediate credit conclusion is therefore measured. The newly available Macau Branch disclosure is supportive evidence for the existence of a sizeable, profitable Macau franchise and for the quality of the branch's audited reporting process. It does not remove the central information constraint: public FY2025 company-consolidated and Hong Kong Branch financials, current Hong Kong RBC capital data, detailed investment-asset risk, surrender behaviour and the economics of the 2028 first call on the subordinated notes are still unconfirmed. For senior issuer-credit assessment, the new information modestly improves evidence on the Macau component of the franchise. For subordinated bondholders, it does not by itself improve the evidence on regulatory capital headroom or call probability.

2. Industry Position and Franchise Strength

China Life Overseas has a long-established position in Hong Kong and Macau and benefits from the China Life brand, group affiliation and access to bancassurance and intermediary distribution. The Company profile describes more than 90 years of Hong Kong history and positions the company as a major Chinese-funded insurer and institutional investor in Hong Kong. The offering circular described a leading historical position in both Hong Kong and Macau. These attributes matter for credit because life insurance is built on durable policyholder confidence and distribution relationships, not only on a single year's reported premium income. A well-recognised brand and a large in-force customer base can support premium collection, investment scale and market access, particularly where customers are choosing long-term savings and protection products.

The Macau Branch's FY2025 premium business income of MOP12.95bn confirms that Macau is not an immaterial extension of the group franchise. At the same time, the figure has a precise limitation. It is a Macau Branch premium measure under the Gazette's branch-level presentation, not the company's consolidated premium income, Hong Kong Branch premium income, annualised premium or new-business value. It does not indicate the split between new and renewal business, the product guarantee burden, acquisition cost, persistency, distribution compensation or margin. The 2025 profit after tax of MOP1.23bn is similarly supportive but cannot be converted into a company-wide ROE or used to infer the profitability of Hong Kong business.

Hong Kong remains the other core franchise. Hong Kong Insurance Authority provisional statistics for January to December 2025 identify China Life, as reported under the IA's China Life label, with direct individual new-business annualised premiums of HKD12.52bn, around 7.4% of the reported market total of HKD168.55bn. This is useful IA-reported market-position evidence, but it is not a set of financial statements for China Life Overseas. The same statistics show low shares by policy count and single premiums relative to annualised premiums, which may indicate a business mix different from the market aggregate. It does not prove profitability, capital consumption or the attribution of every statistic to the wider Company. The correct credit reading is that China Life Overseas has meaningful evidence of franchise scale in both core markets, but public data are insufficient to translate market presence into an audited company-wide earnings or capital conclusion.

The franchise also has risks that a premium headline cannot resolve. Hong Kong and Macau life insurance demand is exposed to consumer confidence, interest-rate competition from deposits and wealth products, travel and cross-border activity, distribution rules and sales-conduct requirements. A decline in new business would initially be a growth and earnings issue; a larger credit concern would arise if it coincided with higher surrender or lapse activity in the in-force book, forcing asset sales when investment values are under pressure. The available Macau filing does not disclose surrender ratios, surrender-value payments, policy duration, customer geography or product guarantees. It should therefore be regarded as evidence of a current operating base, not proof that liability behaviour or ALM risk is benign.

3. Segment Assessment

China Life Overseas' credit profile is dominated by long-term insurance and retirement-related business, with investment management and other geographic operations providing additional breadth. The 2023 offering circular's company-consolidated FY2022 data showed life and annuity premiums of HKD44.21bn, about 89.9% of reported premium income, and retirement-benefit contributions of HKD4.85bn, about 9.9%. Hong Kong and Macau accounted for most first-year premiums. These data establish the historical direction of the business mix but are not an FY2025 segment disclosure.

The Macau Gazette's operating account is identified as life and pension business. It recorded MOP12.95bn of direct gross premiums. It also reports policyholder-related outflows and changes in technical provisions that are material to interpreting a life insurer's income. This presentation reinforces that the branch should not be analysed with an operating-company revenue-minus-EBITDA framework. The principal credit questions are the sufficiency of technical provisions, the quality and liquidity of investment assets backing them, the durability of policyholder funding, regulatory capital and the potential interaction between market stress and surrender demand.

The Macau Branch earned MOP2.41bn of financial income in the operating statement and MOP1.04bn of gains on financial investments in the profit-and-loss statement. Those are meaningful contributors to the reported MOP1.23bn after-tax profit. They also show why the quality of future earnings cannot be assessed merely from premium income: investment returns and realised valuation gains can be sensitive to interest rates, credit spreads, asset allocation and realised-sale decisions. The summarized filing does not disclose the composition, credit quality, duration, unrealised gains/losses or liquidity of the relevant investment portfolio. The results should thus be read as a useful branch profitability snapshot, not evidence that investment risk has diminished at company level.

The historic distribution mix in the offering circular was heavily bancassurance-led, with intermediaries also important. Such channels can deliver volume and access to high-net-worth or cross-border customers but can be sensitive to bank sales priorities, competition from deposit products, commission costs and conduct regulation. The Macau filing provides no FY2025 channel data. It cannot answer whether the branch's premium income reflects recurring business, new sales, product repricing, a shift in product mix or one-off demand.

4. Financial Profile and Analysis

The best new financial evidence is branch-specific. At 31 December 2025, the Macau Branch reported total assets of MOP100.64bn and total liabilities of MOP93.11bn, leaving total net situation of MOP7.53bn. Assets included MOP72.85bn of tangible and financial investments, MOP14.22bn of reinsurers' share, MOP7.45bn of deposits with credit institutions and MOP6.64bn of accrued income and deferrals. The balance sheet also showed MOP11.64bn of financial investments classified as related to technical provisions and MOP66.34bn of credit-debt fluctuation adjustments related to technical provisions. These categories demonstrate that the branch's balance sheet is investment-intensive and closely connected to insurance reserves. They should not be summed mechanically with other reported investment figures without the full underlying accounting notes.

Technical provisions of MOP51.30bn were the largest liability line. Other material balances included MOP14.41bn due to reinsurers and MOP24.89bn due to insured persons within general creditors. The latter includes amounts shown under the local balance-sheet presentation and should not be treated as debt equivalent to bank funding. Nonetheless, the scale of policyholder- and reinsurance-related obligations explains why bondholder analysis must start with the insurer liability hierarchy. Policyholders and non-subordinated creditors rank ahead of the Hong Kong Branch's dated subordinated capital bonds under the 2023 offering circular. The Macau Branch filing does not alter that ranking.

The operating account shows gross premiums of MOP12.95bn, reinsurance recoveries and commission income, financial income of MOP2.41bn and a reduction in technical provisions of MOP3.52bn. The major expense-side items include commissions of MOP1.16bn, direct-insurance discounts of MOP1.06bn, financial charges of MOP1.69bn, direct gross claims and policyholder items, including MOP14.20bn of policy maturities. The presentation is not designed to calculate an operating margin comparable with an industrial company. Its importance is instead that it confirms material policyholder cash-flow activity and substantial investment-income dependence within a profitable branch operation.

The branch recorded MOP492.92m of operating profit and MOP1.04bn of financial-investment gains, leading to MOP1.25bn of pre-tax profit and MOP1.23bn of after-tax profit. A positive result and MOP7.53bn reported net situation are supportive, but they are not enough to establish regulatory-capital headroom. The summary statements do not provide a Macau solvency measure, a Hong Kong RBC ratio, capital tiers, prescribed-capital requirement, stress sensitivity or an asset-liability duration gap. They do not disclose cash-flow statements or debt maturities. Consequently, the filing improves transparency on one operating branch but leaves the principal capital and liquidity questions for the Company and the Hong Kong Branch open.

For wider issuer context, the last detailed public company-consolidated financial series found is the 2020-2022 audited information in the 2023 offering circular. It showed insurance premium revenue declining from HKD68.93bn in 2020 to HKD49.15bn in 2022, net investment income declining to HKD8.29bn in 2022 and total equity falling to HKD23.08bn. Profit for 2022 increased to HKD3.16bn, but total comprehensive income was negative HKD4.22bn. This history demonstrates the sensitivity of a life insurer's capital and comprehensive income to investment-market movements. The old figures should not be used to derive a FY2025 trend or ratios with Macau Branch MOP figures; their continuing relevance is analytical rather than comparative.

The financial conclusion is cautiously supportive but incomplete. The branch-level evidence confirms a profitable FY2025 Macau operation with substantial investment assets and a positive net situation. The lack of comparable branch history and the absence of company-wide FY2025 audited data prevent an assessment of whether earnings, capital quality or liquidity are strengthening across the issuer. For bondholders, the appropriate next step is confirmation of the latest Hong Kong regulatory capital, company and Hong Kong Branch financials, investment-asset composition and the linkage between capital resources and the 2028 call.

There are several reasons to keep the new data in this deliberately narrow place in the credit analysis. First, life-insurer accounting can produce significant differences between statutory branch presentations, company consolidated financial statements and solvency reporting. The Macau Branch's positive result and net situation are observable facts in the published source. They are not, by themselves, a measure of distributable capital, excess capital, unrestricted liquidity or capital eligible for a different regulator's solvency calculation. The published summary expressly omits the disclosures contained in the underlying audited financial statements. Investors should not try to recreate those missing notes by treating the total assets or investment assets as a proxy for capital headroom.

Second, the operating-account results need a liability-side reading. A life insurer may collect significant premiums, pay policy maturities, add or release provisions, earn investment income and recognise financial-investment gains in the same year. The resulting after-tax profit is useful, but it is only one output of a balance-sheet business. A durable credit improvement would require evidence that the insurer can preserve policyholder confidence, meet contractual cash flows, maintain suitable investment returns and absorb market shocks without material erosion of regulatory capital. The Macau Branch filing has not supplied the time-series or risk disclosures required to make that judgement for the Company.

Third, currency is a further reason to avoid false precision. The Macau Branch source is denominated in MOP, the historic company financial statements in the offering circular are in HKD and the Company profile uses HKD. No currency conversion is made in this report, because conversion would create apparent comparability without resolving entity scope, accounting basis or period presentation. The key analytical result is qualitative: the Macau branch is large enough to matter to the franchise, while no valid arithmetic bridge from its MOP balance sheet to the Company or Hong Kong Branch's capital or bond capacity has been disclosed.

Fourth, the filing is best viewed as reducing one specific disclosure uncertainty rather than resolving the entire information set. Before publication, the public record used for this credit was especially thin on FY2023-FY2025 audited evidence. The Gazette now provides a current audited underlying source for the Macau branch. It does not fill the missing evidence for the Hong Kong Branch, where the subordinated securities were issued, or the Company consolidated group. That is still a useful improvement for an issuer summary: it lets the report replace a wholly historical Macau assessment with a current branch anchor while preserving the necessary caution at the issuer and security levels.

5. Structural Considerations for Bondholders

China Life Overseas is the relevant company credit, while the USD2.0bn bonds were issued by its Hong Kong Branch. The notes are direct, unconditional, unsecured and subordinated obligations of the Hong Kong Branch. Under the offering circular, they rank junior to present and future policyholders and non-subordinated creditors of the Company, and to obligations ranking senior by law or contract. They rank senior to ordinary shares and junior obligations. The first call date is 15 August 2028 and final maturity is 15 August 2033. Redemption requires regulatory approval.

This hierarchy is more important to the security than a simple reading of branch profitability. The Macau Branch's reported assets are allocated within a branch balance sheet subject to its own regulatory and policyholder obligations. Public materials reviewed here do not establish the legal availability, transferability or fungibility of those assets for a Hong Kong Branch bond payment, nor do they provide a cross-branch recovery analysis. It would be unsafe to imply that MOP100.64bn of Macau Branch assets are collateral, direct support or recoverable resources for the Hong Kong Branch subordinated notes.

Group ownership is a credit support rather than a guarantee. China Life Overseas is wholly owned by China Life Insurance (Group) Company and has strategic value as the group's overseas platform. This may support policyholder confidence, business continuity and the ability to access capital markets. It is not an express PRC government guarantee, a legal parent guarantee of the Company or Hong Kong Branch, or a promise that the subordinated notes will be called in 2028. Parent support, issuer credit and security-level call incentives must remain separate analytical layers.

The legal and economic distinction also affects how investors should think about branch reporting. A branch is ordinarily part of its legal entity, but public branch financial statements may be prepared for local regulatory disclosure and do not necessarily disclose how assets, liabilities, capital, cash or governance are allocated across the legal entity's other branches and subsidiaries. The reviewed source does not provide an inter-branch funding agreement, a legal opinion on asset availability, an account waterfall, a guarantee, collateral or a creditor-sharing arrangement for the notes. The report therefore does not take a position on the extent to which Macau Branch resources are available to other parts of the Company. Lack of evidence should not be translated into either an assertion of full fungibility or an assertion of ring-fencing.

The same restraint is needed in analysing parent support. In many insurance groups, support may be most likely where it protects policyholders, regulatory standing, brand integrity or an operating franchise. That does not necessarily make support equally available to preserve the call economics, trading price or spread performance of subordinated creditors. The interests of the policyholder base, supervisory authorities, common-equity capital and subordinated noteholders may diverge in a stress case. A call can be rational in some circumstances and unattractive in others, even if the issuer remains solvent and group support expectations remain material. This is why an investor should keep issuer-credit strength, loss-absorption ranking and call probability as separate workstreams.

No conclusion is made here on the enforcement mechanics of the USD notes beyond the offering-circular ranking language. Detailed security analysis would require confirmation of the trust deed, any supplements or notices, events of default and enforcement limitations, deferral features, regulatory-loss-absorption provisions and any later amendments. These documents were not reviewed in the present update. The absence of that analysis does not weaken the basic ranking conclusion, but it limits investment decisions on an individual security and should be addressed before relying on the notes as a stand-alone trade or relative-value position.

The issuance-time expected S&P rating for the bonds was A-, versus A company ratings disclosed in the Company profile. The notching illustrates the structural point: a subordinated instrument can carry a different risk profile even when the operating franchise and issuer assessment are strong. Current agency rationales and current security ratings have not been obtained in this review, and no conclusion is drawn on current notching or market valuation.

6. Capital Structure, Liquidity and Funding

For an insurer, liquidity analysis is an asset-liability and policyholder-behaviour question as much as a debt-maturity question. The Macau Branch's MOP7.45bn of credit-institution deposits and MOP72.85bn of tangible and financial investments are useful high-level indicators that the branch has a substantial pool of financial assets. However, the summarized statements do not show a contractual maturity ladder, encumbrance, readily realisable value, duration, currency profile, derivatives, stressed surrender scenario or committed bank facilities. They cannot establish whether liquid resources would cover stressed policyholder outflows at the Company or Hong Kong Branch.

The Macau Branch balance sheet includes MOP51.30bn of technical provisions and MOP24.89bn within the insured-person line of general creditors. Its operating account records policy maturities of MOP14.20bn. These disclosed categories reinforce the point that liquidity pressure could emerge through policyholder cash flows and asset realisation, rather than solely through a refinancing date. The accounts do not state whether policy maturities are elevated, normal for the portfolio or offset by recurring premiums and investment cash flows. They should not be characterised as evidence of stress without a time series and notes.

The existing 2022 company-consolidated offering-circular data showed investment assets of HKD419.9bn, with fixed income representing 75.3% and 89.4% of fixed-income investments rated investment grade. The 2025 Gazette data do not update that company-wide portfolio mix. Nor do they identify exposure to property, local-government-related issuers, financial institutions, private assets, funds or assets with low liquidity. A large fixed-income allocation can support recurring income and ALM, but it can also leave capital sensitive to spread widening, downgrades and forced sales if policyholder outflows rise.

The core unconfirmed capital item remains Hong Kong RBC. The prior offering circular reported a 244% solvency ratio at end-2022 under the then-disclosed basis. That historical metric does not substitute for current Hong Kong RBC under the applicable framework, nor does the Macau Branch's MOP7.53bn net situation. The amount of the USD subordinated securities recognised as regulatory capital, any phase-out or recognition limits, common-equity-centred headroom, the buffer over intervention thresholds and capital sensitivity have not been publicly confirmed in the materials reviewed.

Accordingly, the new disclosure does not alter the central call analysis. A profitable and asset-rich Macau Branch may be positive for the broader franchise, but a call of the Hong Kong Branch bonds requires the relevant issuer decision, regulatory approval and an assessment of capital treatment, refinancing economics and group financial policy. It cannot be inferred from the Macau Branch balance sheet or activity statement.

The correct interpretation of the branch deposits and investments is also conditional. Deposits with credit institutions may provide some immediate liquidity at the branch level, while financial investments can generate recurring income and supply liquidity depending on their composition and market conditions. Neither label establishes how quickly the asset can be realised, what valuation loss might be incurred on sale, whether it is pledged or otherwise restricted, or whether it offsets insurance liabilities in a regulatory calculation. Conversely, technical provisions do not automatically imply stress; they are a normal and central feature of a life-insurance balance sheet. The information needed is their composition, duration, guarantee profile, policyholder options, reinsurance treatment and relationship to available assets, which has not been disclosed in the summarized filing.

This limitation matters in a changing interest-rate environment. Higher yields can improve prospective reinvestment returns but can also create valuation pressure on existing fixed-income holdings; lower yields can support market values but create reinvestment and guarantee challenges depending on liability duration and product design. Credit-spread widening, downgrades or illiquid-asset valuation changes can have another effect. Without the portfolio and ALM disclosures, the direction and magnitude of these sensitivities cannot be assumed. The historically negative Company comprehensive income in 2022 is a reminder that accounting and market valuation can matter even where reported profit is positive, but it is not evidence that the Macau Branch or Company experienced a comparable FY2025 outcome.

The funding question has two layers. At operating level, premiums, investment cash flows, reinsurance and policyholder payments shape the insurer's liquidity. At capital-markets level, the Company and its Hong Kong Branch need continued access to refinancing for instruments that are economically or regulatorily appropriate. The Macau Branch filing gives evidence on the first layer only in summarized local form. It does not show the Company-wide debt maturity profile, bank facilities, collateral, currency hedge, interest-rate hedge, external funding plan or internal liquidity transfer arrangements. The 2028 call question belongs primarily to the second layer, although it is affected by the first through capital and policyholder outcomes.

For this reason, investors should treat any future disclosure of capital ratios cautiously as well. A ratio can improve because of earnings retention, lower risk charges, market movements, changes in asset allocation, debt recognition, reinsurance or regulatory methodology. A strong ratio is most useful when accompanied by the amount and quality of capital, prescribed or required capital, sensitivities and an explanation of drivers. A single historical solvency ratio, a branch net-situation number or an issuer-profile asset indicator cannot fulfil that role. The next high-value source would be a dated Company or Hong Kong Branch capital disclosure with sufficient detail to connect regulatory headroom to the subordinated securities.

7. Rating Agency View

China Life Overseas' official Company profile lists Moody's A1 insurer financial strength rating as of 29 April 2026 and S&P A local-currency long-term issuer credit and insurer financial strength ratings as of 8 February 2026. The Macau Branch activity statement repeats those dates and rating levels. This corroborates that A-range external ratings were presented by the Company and branch in 2026. It does not provide the full agency methodologies, outlooks, support assumptions, capital assessment, downgrade triggers or instrument notching.

The rating information is supportive in the sense that recognised agencies assign investment-grade assessments to the insurer. It should not be used as a shortcut around the missing capital and liquidity evidence. Ratings incorporate agency judgment and may reflect group support as well as standalone characteristics; they do not constitute a legal guarantee. In particular, a Company insurer financial strength rating is not the same as a rating on the subordinated bonds, and does not determine whether the bonds will be called at the first call date.

The available information permits a limited conclusion: there is no confirmed evidence in the reviewed sources of a rating deterioration. It does not permit a claim that ratings are unchanged in the agencies' most current publications, because full primary releases were not obtained. Future work should obtain Moody's and S&P primary reports, current outlooks, issuer-versus-security rating distinctions, support treatment and quantitative capital triggers.

8. Credit Positioning

On fundamentals, China Life Overseas should be positioned as a sizeable Hong Kong-Macau life insurer with strategic group ownership, a long regional operating history, A-range externally displayed ratings and a large insurance balance sheet. These factors support an investment-grade issuer-credit orientation. The FY2025 Macau Branch filing adds concrete audited evidence that the Macau business has material premium volume, a positive profit and substantial investment assets.

The main differentiator from an issuer with fully transparent insurance financials is disclosure. Professional investors cannot presently use the reviewed public materials to compare current Company or Hong Kong Branch capital ratios, quality of capital, liquidity coverage, investment concentration, duration gap, surrender stress or new-business profitability against peers. Nor can they make a spread-based relative-value judgment because no live price, yield, OAS, CDS or comparable security-level market data have been obtained. The right positioning is therefore qualitative: the franchise and group link are supports, while incomplete current disclosure and subordination constrain confidence in the lower-ranking bonds.

For senior issuer-credit analysis, the branch evidence is modestly favourable but insufficient to change the broad credit view quickly. For the Hong Kong Branch subordinated notes, the evidence limitation is more material because policyholder priority, regulatory capital recognition and call economics matter directly. Investors should not treat the local branch result as a substitute for the quantitative due diligence normally needed for a dated subordinated insurance instrument.

9. Key Credit Strengths and Constraints

Credit strengths

• China Life Overseas is the overseas platform of China Life Insurance (Group) Company, with a longstanding Hong Kong and Macau presence. The strategic relationship supports franchise confidence but is not a guarantee.
• The Company profile and Macau activity statement show A-range external ratings as of specified 2026 dates. These are supportive external reference points, while full rationales remain outstanding.
• The Macau Branch's FY2025 summarized audited filing confirms MOP12.95bn of premium business income, MOP1.23bn of after-tax profit, MOP100.64bn of assets and MOP7.53bn of net situation. This provides audited support for the local operating franchise.
• Historical group evidence and Hong Kong IA statistics indicate a large regional insurance platform with meaningful Hong Kong market presence and an investment-intensive balance sheet appropriate to a life insurer.

Credit constraints

• The FY2025 Macau Branch accounts are not consolidated Company financials and cannot be used to infer Hong Kong Branch earnings, capital or liquidity.
• Detailed FY2023-FY2025 Company financials, current Hong Kong RBC, capital-tier composition, ALM information, surrender behaviour, investment-asset breakdown and liquidity ladder are unconfirmed.
• Investment income and gains were material in the Macau Branch's 2025 result, but portfolio composition, unrealised valuation, duration and liquidity are not disclosed in the summarized accounts.
• The USD bonds are subordinated to policyholders and non-subordinated creditors, and redemption is subject to regulatory approval. The relevant 2028 call analysis remains unconfirmed.
• Public rating tables do not replace primary rating reports or prove a current rating/outlook status.

10. Downside Scenarios and Monitoring Triggers

The first downside scenario is pressure on policyholder behaviour. A decline in new business alone would mainly affect growth and future earnings, but a combination of weaker demand, rising lapse or surrender rates and higher surrender-value payments could become a liquidity and capital issue. The potential transmission is from policyholder outflows to asset sales, realised valuation losses, lower capital headroom and greater dependence on subordinated capital. The Macau Branch filing reports material policy maturities but supplies no comparison or surrender metric, so it cannot determine whether this risk is currently increasing.

The second downside scenario is investment-asset stress. Life insurers can be affected by interest-rate movements, spread widening, downgrades and illiquid-asset valuation changes even where income remains positive. The historical Company portfolio was fixed-income oriented, while Macau's current result included substantial investment income and financial-investment gains. The critical information absent is concentration by issuer, sector, geography, rating and liquidity; impairments and realised/unrealised losses; duration; and the relationship between assets and insurance liabilities. These should be monitored together rather than inferred from headline profit.

The third downside scenario is loss of regulatory-capital headroom. A branch net-balance-sheet measure is not a Hong Kong RBC ratio. The most relevant triggers are disclosure of lower RBC headroom, increased reliance on Tier 2 or subordinated instruments, regulatory intervention thresholds, adverse market-risk sensitivity and rating commentary on capital adequacy. Any such development would be more consequential for the subordinated notes than the present Macau profitability data.

The fourth downside scenario is a change in support expectations or cross-border constraints. China Life Overseas' strategic role and group ownership may support business continuity, but the legal and economic effect of support in a stress scenario is not fully public in the materials reviewed. Investors should monitor rating-agency support treatment, capital injection history, liquidity arrangements and regulatory constraints on cross-border capital movements. None should be assumed from state ownership alone.

The fifth downside scenario relates specifically to the 2028 call. A lower capital buffer, greater need to retain subordinated capital, higher refinancing cost, negative rating commentary or lack of regulatory approval could affect the call decision even if issuer credit remains investment grade. Conversely, a profitable branch result alone does not show that a call is likely. The key evidence remains Company/Hong Kong Branch regulatory capital treatment, refinancing conditions and stated financial policy.

The downside scenarios should be assessed as a sequence rather than as isolated events. For example, a reduction in new business may initially reduce future earnings and growth. It becomes a more serious credit matter if it is accompanied by lower persistency, an increase in cash-value payments, realised losses on asset sales and a decline in regulatory capital. Likewise, an investment valuation loss may be manageable if it remains unrealised and liquidity is ample, but it becomes more consequential if policyholder outflows require asset disposals or if the loss triggers downgrades, higher capital charges or funding-market caution. The reviewed public record does not show such a sequence in FY2025; it explains why the report retains it as a monitoring framework.

The monitoring framework should also avoid overreacting to individual positive indicators. A positive annual profit can coexist with weaker capital quality, greater use of subordinated capital or a less liquid investment portfolio. A high premium figure can coexist with high acquisition costs, capital-intensive guarantees or weak persistency. A stable issuer rating can coexist with a lower security rating, wider subordinated spread or reduced call probability. Conversely, no single unconfirmed risk should be treated as evidence of deterioration. The practical objective is to obtain a consistent set of Company and Hong Kong Branch data and judge the interactions among franchise, policyholder behaviour, investments, capital and funding.

11. Credit View and Monitoring Focus

China Life Overseas remains an investment-grade-oriented regional life-insurance credit, supported by an established Hong Kong-Macau franchise, strategic group ownership and A-range ratings displayed by the Company. The direction of the central credit view is broadly stable rather than rapidly improving: the newly published Macau Branch statements provide current audited evidence of substantial local premium volume, profitability and investment assets, but the most decision-relevant capital and liquidity information for the Company and Hong Kong Branch is still absent. A sudden change in the issuer assessment appears less likely than a change in security-level sentiment if new information reveals reduced Hong Kong RBC headroom, investment losses, policyholder outflows or greater reliance on subordinated capital.

The FY2025 Macau Branch filing modestly strengthens confidence in the local operating franchise. MOP12.95bn of premium business income, MOP1.23bn of after-tax profit and MOP100.64bn of assets show that the Macau operation is material and profitable. However, its account presentation also reinforces the insurance-specific risk framework: technical provisions, policyholder balances, reinsurance and investment results dominate the balance sheet and earnings. The absence of detailed portfolio, liability and capital information means that the filing supports the credit floor through franchise evidence but does not lift the credit ceiling through demonstrated group-wide capital headroom.

For the Company, the most important supports remain the China Life franchise, the regional scale of the insurance operations, strategic group relevance and A-range external ratings. The principal constraints are public-data limitations after 2022 for detailed Company financials, current Hong Kong RBC and capital composition, the quality and liquidity of investment assets, policyholder behaviour and full rating-agency rationale. The audited Macau Branch numbers should be incorporated into the evidence base, but never labelled as consolidated Company or Hong Kong Branch figures.

For holders of the Hong Kong Branch dated subordinated capital bonds, the distinction is sharper. The instruments rank behind policyholders and non-subordinated creditors and require regulatory approval for redemption. The Macau Branch's profit, assets and net situation are not evidence that the securities will be called in 2028, nor do they establish a recovery pool for those bondholders. The relevant credit questions are regulatory-capital recognition, common-equity-centred headroom, policyholder liquidity stress, refinancing conditions, rating treatment and the issuer's call policy.

The credit view would improve in evidence quality if China Life Overseas or the Hong Kong regulator disclosed current Company/Hong Kong Branch audited financials, RBC capital, investment-asset and insurance-liability detail, and if rating agencies provided updated primary rationales. It would require reassessment if capital headroom weakened, asset valuations or impairment losses rose, policyholder withdrawals increased, external support expectations diminished or the 2028 call became economically or regulatorily less likely. Until those questions are answered, the balanced conclusion is that a current audited Macau Branch result supports the operating-franchise assessment, while issuer-wide and subordinated-security analysis remains necessarily cautious.

12. Short Summary & Conclusion

China Life Overseas is a Hong Kong-Macau life insurer and China Life Group's overseas platform, supported by a longstanding franchise and A-range ratings displayed by the Company. FY2025 Macau Branch audited summary accounts show MOP12.95bn of premium income, MOP1.23bn of after-tax profit and MOP100.64bn of assets, but these are Macau Branch-only figures. They do not answer the key remaining questions on Company/Hong Kong Branch RBC, investment risk, liquidity or the 2028 call of the subordinated bonds.

13. Sources

Primary and regulatory sources

• Macau Official Gazette No. 21, 27 May 2026, China Life Insurance (Overseas) Company Limited Macau Branch FY2025 summarized audited financial statements and activity statement.
  https://bo.dsaj.gov.mo/bo/ii/2026/21/anotariais_cn.asp?printer=1
• China Life Insurance (Overseas) Company profile, accessed for the prior and current coverage update.
  https://www.chinalife.com.hk/about-us/clo
• HKEX offering circular for China Life Insurance (Overseas) Company Limited, Hong Kong Branch, USD2.0bn 5.35% dated subordinated capital bonds due 2033, dated 8 August 2023 and published 16 August 2023.
  https://www1.hkexnews.hk/listedco/listconews/sehk/2023/0816/2023081600153.pdf
• Hong Kong Insurance Authority, provisional statistics on Hong Kong long-term business, January to December 2025, updated 21 April 2026.
  https://www.ia.org.hk/en/infocenter/statistics/files/4q25long.pdf

Unverified or pending items

• Detailed FY2023-FY2025 audited financial statements of China Life Overseas and the Hong Kong Branch were not obtained. The Macau Gazette disclosure is a branch-level summary and is not a substitute.
• Current Hong Kong RBC, capital tiers, subordinated-capital recognition, intervention buffer and sensitivities are not confirmed.
• FY2025 portfolio composition, credit quality, sector/geographic concentration, duration, liquidity, unrealised gains/losses and impairment detail are not confirmed for the Company or Hong Kong Branch.
• Policyholder surrender/lapse data, cash-value payments, new-business value, product guarantees, CSM and distribution economics are not confirmed.
• Moody's and S&P full primary reports, current outlooks, support assumptions, security notching and rating triggers were not obtained.
• Current bond price, yield, spread, liquidity, individual-documentation updates and 2028 call policy remain unconfirmed.